Effect of gene therapy for quality of life and change of objective indexes blood supply of the lower limbs in patients with peripheral atherosclerosis

  • Authors: 1, 1, 1
  • Affiliations:
    1. Ярославский государственный медицинский университет, Ярославль, ул. Революционная, д. 5, 150000, Российская Федерация Областная клиническая больница, г. Ярославль, ул. Яковлевская, д. 7, 150062, Российская Федерация
  • Issue: Vol 8, No 4 (2015)
  • Pages: 318-324
  • Section: Original articles
  • URL: https://vestnik-surgery.com/index.php/journal/article/view/2
  • DOI: https://doi.org/10.18499/2070-478X-2015-8-4-318-324
  • Cite item

Abstract


The purpose of the study To evaluate the results of gene therapy in patients with HODLLA stage II and III within the period up to 3 years. Materials and methods We have experience of using the first registered domestic genetic drug based on gene vegf 165 in treatment of patients with chronic obliterating diseases of lower limb arteries (HODLLA) for stages II and III of A.V. Pokrovsky - Fontaine in the amount of 65 observations. Of these, traced long-term outcomes in terms of over 3 years, 45 people (II stage - 27 patients, III st. N = 18). The average age of patients was 63,3 ± 5,8. Evaluation results performed depending on the initial stage of the disease. The efficacy of treatment was evaluated by the following methods: 1. Determination of the quality of life (physical and psychological components of health) was made in using Russian version of the standard questionnaire SF 36; 2. pain-free walking distance was determined during the treadmill-test (walking speed of 1 km/h, the angle of 0°); 3. save the leg; 4. the survival rate of patients. Results and their discussion Significantly improved quality of life at 1 year follow-up, and then save a positive result for 3 years for all patients with stage II disease. The average value of the physical health component for inclusion in the clinical trial was 29,0 ± 6 points. During the first year PH had increased to 42,2 ± 8. In the future, marked by a further increase to the level of 47,6 ± 9 to the end of the observation period. The mental component of health initially 34,2 ± 4,0 points, in the first year of observation MH increased to 52,9 ± 5, and 2 and 3 years was stabilized and reached 54,8 ± 6. The average value of pain-free walking distance was 159 ± 123 m, to the end of 1 year - 676 ± 542 m, to the end of 2 year it was 704 ± 475 m, 3 years - 654 ± 415m. A safety limb throughout the observation period was 100%, survival rate - 88.9%. Patients with stage III HODLLA original value PH was 22,3 ± 1,3 points. During the first year had increased to 31,4 ± 9,3 and further noted its gradual increase to 37,5 ± 9,0 at the end of 3 years. MH changes were more significant. When included in the CI it was 25,2 ± 4,3 points, for the first year of follow-up increase in 36,2 ± 11. For 2 and 3 years, he continued to grow and reached 51,1 ± 8,3 points. Initially, the average value of pain-free walking distance was 31,5 ± 25m, to the end of 1 year - 200 ± 107m, after 2 years - 274 ± 72m, after 3 years - 271 ± 63m. Save the limb for the entire observation period - 78%. Three observations in the first year and one in the second year of lower limb amputations performed at the level of the thigh on the progression of chronic ischemia. The survival rate in this group was 100%. Conclusion The use of a single course of treatment based on gene vegf 165 in patients with stage II and III of HODLLA A.V. Pokrovsky-Fontaine classification leads to a stable positive effect in the large majority of patients in long-term period of three years and does not require repeated courses of gene therapy. In 82% of patients showed improvement, both physical and, to a greater extent, the psychological component of quality of life; It showed a significant increase in pain-free walking distance, increased their daily activity. All patients showed good tolerability and lack of side effects; fixed stabilization of the results. The survival rate was 93.3%. Keywords. Atherosclerosis, chronic lower limb ischemia, gene treatment, quality of life

Ярославский государственный медицинский университет, Ярославль, ул. Революционная, д. 5, 150000, Российская Федерация Областная клиническая больница, г. Ярославль, ул. Яковлевская, д. 7, 150062, Российская Федерация

Author for correspondence.
Email: admin@vestnik-surgery.com
д.м.н., доцент, проф. кафедры хирургии института последипломного образования Ярославского государственного медицинского университета; сердечно-сосудистый хирург, врач отделения сосудистой хирургии «Областная клиническая больница», г. Ярославль.

Ярославский государственный медицинский университет, Ярославль, ул. Революционная, д. 5, 150000, Российская Федерация Областная клиническая больница, г. Ярославль, ул. Яковлевская, д. 7, 150062, Российская Федерация

Email: admin@admin.ru
к.м.н., доцент, заведующий кафедрой хирургии института последипломного образования Ярославского государственного медицинского университета; сердечно-сосудистый хирург, заведующий отделением сосудистой хирургии «Областная клиническая больница», г. Ярославль

Ярославский государственный медицинский университет, Ярославль, ул. Революционная, д. 5, 150000, Российская Федерация Областная клиническая больница, г. Ярославль, ул. Яковлевская, д. 7, 150062, Российская Федерация

Email: admin@admin.ru
- аспирант кафедры хирургии института последипломного образования Ярославского Государственного медицинского университета.

  1. Novik A.A., Matveev S.A., Ionova T.I. et al. Otsenka kachestva zhizni bol'nogo v meditsine [Evaluation of the quality of life of the patient in medicine]. 2000; 2: 10-13 (in Russ.).
  2. Brimkulov N.N., Sienkiewicz N.U., Kalieva A.D. Primenenie oprosnika SF-36 dlya otsenki kachestva zhizni. Tsentral'noaziatskiy meditsinskiy zhurnal [The use of SF-36 questionnaire to assess quality of life. The Central Medical Journal]. 1998; 4-5: 236-241 (in Russ.).
  3. Savelyev V.S., Koshkin V.M., Karalkin A.V. Patogenez i
  4. konservativnoe lechenie tyazhelykh stadiy bliteriruyushchego
  5. ateroskleroza arteriy nizhnikh konechnostey [Pathogenesis and conservative treatment of severe stages of atherosclerotic lesions of arteries of the lower extremities]. -M.: MIA, 2010; 214 (in Russ.).
  6. Jaff M.R., Moler E.R. Zabolevaniya perifericheskikh arteriy [Peripheral artery disease]. -M.: GEOTAR Media, 2010; 214 (in Russ.).
  7. Boqueria L.A. Kombinirovannoe lechenie khronicheskoy
  8. ishemii nizhnikh konechnostey s ispol'zovaniem stimulyatorov
  9. angiogeneza. Byulleten' NTsSSKh im. A. N. Bakuleva RAMN [Combined treatment of chronic lower limb ischemia using
  10. stimulants angiogenesis. Bulletin NTSSSH them. A.N. Bakulev
  11. RAMS]. –М., 2004; 5: 11: 326 (in Russ.).
  12. Gavrilenko A.V., Voronov D.A., Bochkov N.P. Kompleksnoe lechenie patsientov s khronicheskoy ishemiey nizhnikh konechnostey s ispol'zovaniem gennykh induktorov angiogeneza: blizhayshie i otdalennye rezul'taty. Kletochnaya transplantologiya i tkanevaya inzheneriya [Complex treatment of patients with chronic lower limb ischemia using gene inducers of angiogenesis: Distribution of patients according to the stage of the disease and the time of observation U.V. Chervyakov et al. Effect of gene therapy for quality of life and change of objective indexes blood supply of the lower limbs in early and late results. Cell transplantation and tissue engineering]. 2011; 6: 3: 84 (in Russ.).
  13. R.V. Deev, U.V. Chervyakov, R. E. Kalinin, A.A. Isaev.
  14. Teoreticheskie i prakticheskie aspekty primeneniya preparata
  15. na osnove nukleinovoy kisloty, kodiruyushchey endotelial'nyy
  16. sosudistyy faktor rosta («Neovaskulgen»). Elektron. tekst. dan. Elektronnyy zhurnal ANGIOLOGIA.ru [Theoretical and practical aspects of the drug on the basis of a nucleic acid encoding vascular endothelial growth factor ("Neovaskulgen"). Given electronic text. Electronic Journal ANGIOLOGIA.ru]. 2011. Access mode for the journal: http:// www.angiologia.ru/journal_angiologia/001_2011 (in Russ.).
  17. Shvalb P.G., Kalinin R.E, Gryaznov S.V. Bezopasnost' i
  18. kratkosrochnaya effektivnost' genoterapevtichesogo preparata
  19. u patsientov s khronicheskoy ishemiey nizhnikh konechnostey.
  20. Kardiologiya i serdechno-sosudistaya khirurgiya [The safety
  21. and effectiveness of short-term gene therapeutic drug in patients with chronic lower limb ischemia. Cardiology and cardiovascular surgery]. 2011; 4: 4: 23-27 (in Russ.).
  22. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 2004; 25: 4: 581-611.
  23. Grundmann S. J., Piek J., Pasterkamp G. Arteriogenesis: basic mechanisms and therapeutic stimulation. Eur J Clin Invest. 2007; 37: 10: 755-766.
  24. Powell R.J., Simons М., Mendelsohn F.J. Results of a Double-Blind, Placebo-Controlled Study to Assess the Safety of Intramuscular Injection of Hepatocyte Growth Factor Plasmid to Improve Limb Perfusion in Patients With Critical Limb Ischemia. Circulation. 2008; 118: 58-65.
  25. Westerweel P. E. A study of neovascularization in the rat ischemic hindlimb using Araldite casting and Spalteholtz tissue clearing. Cardiovasc Pathol. 2005; 14: 6: 294-297.
  26. Parfenova E.V., Tkachyk V.A. Therapeutic angiogenesis: Achievements, Challenges and Prospects. Cardiology Gazette. 2007; 2: 4: 5-15.
  27. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000; 6: 4: 389-395.
  28. Chervyakov U.V., Staroverov I.N., Nersessyan E.G., Isaev A.A., Deev R.V. Terapevticheskiy angiogenez v lechenii bol'nykh khronicheskimi obliteriruyushchimi zabolevaniyami arteriy nizhnikh konechnostey. Angiologiya i sosudistaya khirurgiya [The therapeutic angiogenesis in patients with chronic obliterating diseases of lower limb arteries. Angiology and Vascular surgery]. 2012; 18: 3: 19-26 (in Russ.).

Views

Abstract - 191

PDF (Russian) - 132

PlumX

Dimensions


Copyright (c) 2015 ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies